The European Commission has signed a contract with Gilead Sciences, the company behind remdesivir, that will make the drug available to around 500,000 patients. The drug will certainly be necessary if vaccination is not widespread, says Doctor Tomáš Cihlář, who is Gilead Sciences’ vicepresident for virology and the leader of the research team that developed redemsivir.